SAN FRANCISCO, May 3, 2011 /PRNewswire/ -- Vista Partners
announced today that it has initiated coverage on Cellmid Ltd.
(ASX: CDY) (the "Company") with a twelve month target price of AUD
$0.10. Ross
Silver, Principal Analyst at Vista Partners stated, "We
believe Cellmid represents a significant value proposition to a
potential collaborator considering the breadth of the Company's
midkine ("MK") patents. The size of the market its therapeutics
could compete, if approved, is in excess of $15 billion." Mr. Silver continued, "Cellmid has
a large portfolio of patents surrounding MK and owns 21 patent
families worldwide. Cellmid plans to monetize this portfolio
through two segments: Diagnostics and Therapeutics. The diagnostic
programs are in a more advanced stage and are poised to face
regulatory approvals first. The therapeutic programs are in
pre-clinical trials; however they involve high value antibody
candidates with early partner/licensing potential." Mr. Silver
concluded, "Cellmid is the second Australian biotechnology company
we have covered, the previous Australian biotech company we covered
was named Arana and they were acquired by Cephalon (ticker: CEPH)
for $318M in 2009."
To download a FREE copy of the Cellmid Ltd. research report,
please visit www.vistapglobal.com and complete the research form to
gain access to the report.
About Vista Partners:
Vista Partners LLC, founded in 2005, is a Registered Investment
Advisor in the States of California and Oregon. The firm's professional staff has
backgrounds in finance, corporate communications and investment
banking. Vista Partners LLC has built a name for itself in the
small cap space due to its selection of profitable investment
ideas.
Disclaimer & Disclosure:
For a full list of disclaimers and disclosures, please visit our
website www.vistapglobal.com or click here.
Contact:
877.215.4813 or info@vistapglobal.com
SOURCE Vista Partners